<DOC>
	<DOC>NCT00918411</DOC>
	<brief_summary>The purpose of this study is to explore and examine endpoints that allow evaluation of the "clinically significant improvements, focusing on the patient's chief complaint and the severity of major IBS symptoms" by this drug in patients with diarrhea-predominant irritable bowel syndrome (IBS).</brief_summary>
	<brief_title>A Preliminary Study to Explore Clinical Endpoints in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Ramosetron</mesh_term>
	<criteria>Patients meeting the Rome III Diagnostic Criteria Loose (mushy) or watery stools within the last 3 months Patients having hyperthyroidism or hypothyroidism</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>diarrhea</keyword>
	<keyword>IBS</keyword>
	<keyword>Colonic diseases</keyword>
	<keyword>YM060</keyword>
</DOC>